There are 2949 resources available
1425MO - Effects of elemental diet for gastrointestinal adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil (EPOC 2 study: JFMC49-1601-C5): A phase III randomized controlled trial
Presenter: Hiroya Takeuchi
Session: Mini Oral - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
612MO - Clinical impact of somatic alterations in prostate cancer patients with and without previously known germline BRCA1/2 mutations: Results from PROREPAIR-A study
Presenter: Rebeca Lozano Mejorada
Session: Mini Oral - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
1674MO - ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: Implications for SARS-CoV-2
Presenter: Riyue Bao
Session: Mini Oral - SARS-CoV-2 and cancer 2
Resources:
Abstract
Slides
Webcast
LBA81 - Keeping exhausted T-cells in check in COVID-19
Presenter: Pierre Van Mol
Session: Mini Oral - SARS-CoV-2 and cancer 2
Resources:
Abstract
Slides
Webcast
706MO - Association between human papillomavirus (HPV) infection and outcome of perioperative nodal radiotherapy for penile carcinoma
Presenter: Andrea Necchi
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
707MO - Longitudinal cohort analysis of patients with metastatic penile cancer treated in a large quaternary academic centre
Presenter: Wing Kin Liu
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
708MO - Metachronous contralateral testicular cancer in the cisplatin era: A population-based cohort study
Presenter: Ragnhild Hellesnes
Session: Mini Oral - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1621MO - Long-term efficacy, tolerability and overall survival in patients (pts) with unresectable or metastatic (U/M) PDGFRA D842V-mutant gastrointestinal stromal tumour (GIST) treated with avapritinib: NAVIGATOR phase I trial update
Presenter: Robin Jones
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1622MO - Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study
Presenter: John Zalcberg
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1623MO - Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I study
Presenter: Filip Janku
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast